|1.||Aizawa, Yoshifusa: 3 articles (01/2015 - 01/2012)|
|2.||Urich, Daniela: 3 articles (03/2010 - 11/2007)|
|3.||Gutiérrez, Jeydith: 3 articles (03/2010 - 11/2007)|
|4.||Liu, James K: 3 articles (11/2007 - 03/2004)|
|5.||Masuyama, Tohru: 2 articles (07/2015 - 06/2015)|
|6.||Imanaka, Takahiro: 2 articles (07/2015 - 06/2015)|
|7.||Nishimura, Machiko: 2 articles (07/2015 - 06/2015)|
|8.||Miki, Kojiro: 2 articles (07/2015 - 06/2015)|
|9.||Horimatsu, Tetsuo: 2 articles (07/2015 - 06/2015)|
|10.||Fukunaga, Masashi: 2 articles (07/2015 - 06/2015)|
10/01/1991 - "The findings suggest that I-C papaverine, although effective in treating impotence, is not a panacea, and a large percentage of users (55% in our study) are likely to discontinue the drug within a relatively short period of time."
01/01/1992 - "The results suggest that measurement of corporal clearance of Tc-RBC after intracorporal injection of papaverine may be a useful method in detecting venous leak, and could be used as a screening test in patients with erectile dysfunction."
02/01/1995 - "This study was done as a phase I, placebo controlled, nonblinded investigation of the safety and efficacy of a topical papaverine gel in the treatment of erectile dysfunction. "
02/01/1990 - "Five patients recovered from erectile dysfunction and 1 patient showed papaverine-induced full erection. "
01/01/1990 - "A simple test to predict the outcome of intracavernous papaverine treatment would be helpful in the management of erectile dysfunction. "
10/01/2004 - "Papaverine delivery to the internal mammary artery pedicle effectively treats spasm."
04/01/2001 - "Consequently, to relieve perioperative spasm of the IMA, application of papaverine injected into the periarterial tissues of its pedicle was considered to be a safe and effective alternative to topical or intraluminal application."
08/01/2005 - "The strongest evidence for safe prevention of spasm is for papaverine given topically and periarterially, however many studies have also shown no benefit and thus no treatment at all is an entirely acceptable strategy."
01/01/2014 - "Papaverine (3%, 60 mg) was dropped into the internal carotid artery cistern to relieve vascular spasm and act on the oculomotor nerve intentionally at the same time. "
10/01/2013 - "A maximum of 3 mL of a 1 mg/1 mL diluted papaverine solution was injected intravascularly (intraluminally) for spasm prophylaxis. "
|3.||Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage)
01/01/1995 - "Papaverine was effective in dilating narrowed arteries in most patients with symptomatic vasospasm caused by subarachnoid hemorrhage. "
02/01/2001 - "It remains controversial whether the intra-arterial administration of papaverine (IAP) is effective in reversing vasospasm-associated cerebral hypoperfusion after aneurysmal subarachnoid hemorrhage. "
04/01/1998 - "We described the techniques and efficacy of intra-arterial papaverine hydrochloride infusion (IA-PAP) for symptomatic vasospasm due to aneurysmal subarachnoid hemorrhage based on our experience and review of the literature. "
11/01/1995 - "This study examined the relationship between papaverine-sensitive and -insensitive components of vasospasm, arterial contractility and compliance, and time after subarachnoid hemorrhage (SAH) in dogs. "
01/01/1995 - "Effect of intra-arterial papaverine on cerebral blood flow in vasospasm after subarachnoid hemorrhage: A study using single-photon emission computed tomography."
03/01/2004 - "Efficacy of multiple intraarterial papaverine infusions for improvement in cerebral circulation time in patients with recurrent cerebral vasospasm."
09/01/2002 - "The efficacy of papaverine administration by different routes for the treatment of experimental acute cerebral vasospasm."
07/01/2001 - "Efficacy of controlled-release papaverine pellets in preventing symptomatic cerebral vasospasm."
10/01/1983 - "[Topical application of papaverine for cerebral vasospasm using prolonged release pellet--experimental studies]."
12/01/2006 - "Use of either intra-arterial or intracisternal papaverine as an alternative treatment of refractory cerebral vasospasm has been associated with various complications including haemodynamic instabilities. "
04/01/2014 - "A 5-mg dose of intracoronary papaverine is as effective as a 10-mg dose in inducing maximal hyperemia. "
04/01/2014 - "The primary aim of this study was to validate the assessment of IMR in a large animal model, and the secondary aim was to compare two doses of intracoronary papaverine, 5 and 10 mg, for induction of maximal hyperemia and its evolution over time. "
07/01/2015 - "In conclusion, the increase in blood flow of lower limb during maximal hyperemia varied between individuals and maximal hyperemia can be achieved with 30 mg of papaverine for the SFA lesion. "
07/01/2015 - "A dose of 30 mg of intra-arterial papaverine was sufficient to achieve maximum hyperemia (%IBF: range 219-769 %). "
07/01/2015 - "Thermodilution-derived mean transit time (Tmn) was obtained at baseline and during pharmacological hyperemia with incremental dose of intra-arterial papaverine (10, 20, 30, and 40 mg) using a 0.014-inch pressure/temperature sensor-tipped wire in the superficial femoral artery (SFA). "
|3.||Diclofenac (SR 38)
|7.||Vasodilator Agents (Vasodilators)
|8.||Histamine (Histamine Dihydrochloride)
|3.||Angioplasty (Angioplasty, Transluminal)